DDrare: Database of Drug Development for Rare Diseases

Searched query = "HTLV-1-associated myelopathy", "Tropical spastic paraparesis", "HTLV-1", "HTLV-I-associated myelopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Amniotic Epithelial Cells; Amniotic epithelial cells; Bortezomib; Ciclosporin; Costicosteroids; Cyclophosphamide; Doxorubicin; Doxorubicin Hydrochloride; Doxorubicin hydrochloride; Etoposide; Filgrastim; Hu MiK-Beta-1; Human interferon beta; Interferon alfa; Interferon beta; Interferon beta-1a; KW-0761; KW-0761 0.3 mg/kg IV; Lamivudine; Lenalidomide; Methylprednisolone; Mogamulizumab; NK Cells; NK cells; Nivolumab; Other: Laboratory Biomarker Analysis; Other: Pharmacogenomic Study; Pentosan polysulfate; Pentoxifylline; Prednisolone; Prednisone; Propantheline; Propantheline Bromide; Raltegravir; Raltegravir and Zidovudine; Recombinant human interferon beta-1a; Recombinant interferon alfa; Sulfate; Tamibarotene; Valproic acid; Valproid acid plus corticosteroids; Vincristine; Vincristine Sulfate; Vincristine sulfate; Zidovudine; Zidovudine/lamivudine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04301076 (ClinicalTrials.gov)	June 15, 2020	6/3/2020	Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (EPOCH) for Adult T-Cell Leukemia-Lymphoma (ATL)	A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)	Acute Adult T-Cell Leukemia/Lymphoma;Adult T-Cell Leukemia/Lymphoma;Chronic Adult T-Cell Leukemia/Lymphoma;HTLV-1 Infection	Drug: Cyclophosphamide;Drug: Doxorubicin Hydrochloride;Drug: Etoposide;Drug: Lenalidomide;Drug: Prednisone;Drug: Vincristine Sulfate	National Cancer Institute (NCI)	NULL	Recruiting	18 Years	N/A	All	30	Phase 1	United States
2	NCT01274533 (ClinicalTrials.gov)	December 2010	10/1/2011	Lenalidomide in HTLV-1 Adult T-Cell Leukemia	A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma	Adult T Cell Leukemia/Lymphoma	Drug: Lenalidomide	Columbia University	Celgene Corporation	Completed	18 Years	N/A	All	4	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04301076
(ClinicalTrials.gov)

June 15, 2020

6/3/2020

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (EPOCH) for Adult T-Cell Leukemia-Lymphoma (ATL)

A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)

Acute Adult T-Cell Leukemia/Lymphoma;Adult T-Cell Leukemia/Lymphoma;Chronic Adult T-Cell Leukemia/Lymphoma;HTLV-1 Infection

Drug: Cyclophosphamide;Drug: Doxorubicin Hydrochloride;Drug: Etoposide;Drug: Lenalidomide;Drug: Prednisone;Drug: Vincristine Sulfate

National Cancer Institute (NCI)

NULL

Recruiting

18 Years

N/A

All

Phase 1

United States

NCT01274533
(ClinicalTrials.gov)

December 2010

10/1/2011

Lenalidomide in HTLV-1 Adult T-Cell Leukemia

A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma

Adult T Cell Leukemia/Lymphoma

Drug: Lenalidomide

Columbia University

Celgene Corporation

Completed

18 Years

N/A

All

Phase 2

United States